Effects of Bone-Targeted Agents on Cancer Progression and Mortality

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

(2013)   LANCET

CD8+ T Cells Regulate Bone Tumor Burden Independent of Osteoclast Resorption

(2011) K. Zhang et al.   CANCER RESEARCH

High Phosphoantigen Levels in Bisphosphonate-Treated Human Breast Tumors Promote V 9V 2 T-Cell Chemotaxis and Cytotoxicity In Vivo

(2011) I. Benzaid et al.   CANCER RESEARCH

Advances in the Biology and Treatment of Bone Disease in Multiple Myeloma

(2011) Noopur Raje et al.   CLINICAL CANCER RESEARCH

Can bisphosphonates improve outcomes in patients with newly diagnosed multiple myeloma?

(2011) Gareth J. Morgan   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Anticancer evidence for zoledronic acid across the cancer continuum

(2011) Luis Costa et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma

(2011) David H. Henry et al.   JOURNAL OF CLINICAL ONCOLOGY

Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial

(2011) Matthew R Smith et al.   LANCET

Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial

(2011) Gareth J Morgan et al.   LANCET ONCOLOGY

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial

(2011) Michael Gnant et al.   LANCET ONCOLOGY

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial

(2011) Luca Gianni et al.   LANCET ONCOLOGY

Molecular mechanisms and clinical applications of angiogenesis

(2011) Peter Carmeliet et al.   NATURE

Prevention and Treatment of Bone Metastases

(2010) E. J. Woodward et al.   CURRENT PHARMACEUTICAL DESIGN

Nitrogen-Containing Bisphosphonates and Cancer Immunotherapy

(2010) P. Clezardin et al.   CURRENT PHARMACEUTICAL DESIGN

A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer

(2010) Mohamed S. Zaghloul et al.   International Journal of Clinical Oncology

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial

(2010) Jack Cuzick et al.   LANCET ONCOLOGY

An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma

(2009) Ravi Vij et al.   AMERICAN JOURNAL OF HEMATOLOGY

Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma

(2009) Michele Moschetta et al.   EUROPEAN JOURNAL OF CANCER

The bisphosphonate zoledronic acid has antimyeloma activityin vivoby inhibition of protein prenylation

(2009) Andreas Guenther et al.   INTERNATIONAL JOURNAL OF CANCER

Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway

(2009) Marta Coscia et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intravenous Bisphosphonates

(2009) Karim Fizazi et al.   JOURNAL OF CLINICAL ONCOLOGY

Antitumor Effects of Doxorubicin Followed by Zoledronic Acid in a Mouse Model of Breast Cancer

(2008) P. D. Ottewell et al.   JNCI-Journal of the National Cancer Institute